<DOC>
	<DOCNO>NCT00231621</DOCNO>
	<brief_summary>The purpose study compare efficacy safety daily topiramate versus placebo treatment obese subject dyslipidemia .</brief_summary>
	<brief_title>A Study Efficacy Safety Topiramate Treatment Obese Subjects With Dyslipidemia</brief_title>
	<detailed_description>Topiramate approve treatment obesity . Studies show topiramate reduces weight obese patient without Type 2 diabetes , may adjunctive benefit reduce triglyceride cholesterol level patient . This double-blind , placebo control study evaluate long-term efficacy topiramate reduction weight triglyceride level obese patient borderline high hypertriglyceridemia , safety tolerability topiramate patient population . The study consist four phase : 4-week enrollment ( screen ) phase , 8-week titration phase ( topiramate dose increase 16mg/day assign dose ) , 52-week maintenance phase , 6-week follow-up . Effectiveness topiramate evaluate multiple measurement change body weight , body mass index , fast serum triglyceride level , cholesterol lipid profile . Safety evaluation include incidence/severity adverse event , vital sign , clinical laboratory result . The hypothesis topiramate compare placebo provide great percent reduction body weight fast serum triglyceride Week 0 ( baseline ) Week 60 . After initial 8-weeks titration phase , patient randomize receive either 96mg ( 48mg twice daily ) 192mg ( 96mg twice daily ) topiramate placebo ( twice daily ) mouth 52 week .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>A Body Mass Index ( BMI ) &gt; = 27 kg/m^2 &lt; 50 kg/m^2 Stable weight least four month prior first enrollment visit Diagnosis dyslipidemia ( serum triglyceride representative mild moderate hypertriglyceridemia low HDL high LDL ) Patients lipid lower medication monotherapy drug least 4 month dose least 2 month prior first enrollment Female patient must postmenopausal least 1 year , surgically incapable childbearing , practice abstinence , practice acceptable method contraception ( require negative pregnancy test ) Contraindication hypersensitivity topiramate Pregnancy , nurse woman plan become pregnant study Enrollment fast triglyceride &lt; 175 &gt; = 1000 mg/dL , and/or LDL &gt; = 190 mg/dL Hyperlipidemia secondary know disease Other significant medical condition cardiovascular liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Triglyceride</keyword>
	<keyword>HDL</keyword>
	<keyword>LDL</keyword>
	<keyword>Diabetes</keyword>
</DOC>